Evidence map›Paper›PMID 37393552›Full record

SynthesisCurrent medicinal chemistry2024

Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.

Xingfen Zhang, Dandi Lou, Rongrong Fu, Feng Wu, Dingcheng Zheng, Xueqiang Ma

Open access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. The association of statin therapy and cancer: a meta-analysis.Lipids in health and disease · 2023 · on this map
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025
    Review
  8. Review
  9. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xingfen ZhangDepartment of Liver Disease, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Dandi LouThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Rongrong FuThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Feng WuDepartment of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Dingcheng ZhengDepartment of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China.
Xueqiang MaDepartment of Hepatobiliary Surgery, Zhuji People's Hospital, Shaoxing, Zhejiang, China.
Ningbo No. 2 Hospital · CNZhejiang Chinese Medical University · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have found a potential role for statins in liver cancer prevention.

objectiveThis study aimed to explore the effect of different types of statins on the incidence of liver cancer.

methodsRelevant articles were systematically retrieved from PubMed, EBSCO, Web of Science, and Cochrane Library databases from inception until July 2022 to explore the relationship between lipophilic statins or hydrophilic statins exposure and the incidence of liver cancer. The main outcome was the incidence of liver cancer.

resultsEleven articles were included in this meta-analysis. The pooled results showed a reduced incidence of liver cancer in patients exposed to lipophilic statins (OR=0.54, p < 0.001) and hydrophilic statins (OR=0.56, p</i> < 0.001) compared with the non-exposed cohort. Subgroup analysis showed that both exposures to lipophilic (Eastern countries: OR=0.51, p</i> < 0.001; Western countries: OR=0.59, p</i> < 0.001) and hydrophilic (Eastern countries: OR=0.51, p</i> < 0.001; Western countries: OR=0.66, p</i>=0.019) statins reduced the incidence of liver cancer in Eastern and Western countries, and the reduction was most significant in Eastern countries. Moreover, atorvastatin (OR=0.55, p</i> < 0.001), simvastatin (OR=0.59, p</i> < 0.001), lovastatin (OR=0.51, p</i> < 0.001), pitavastatin (OR=0.36, p</i>=0.008) and rosuvastatin (OR=0.60, p</i>=0.027) could effectively reduce the incidence of liver cancer, unlike fluvastatin, cerivastatin and pravastatin.

conclusionBoth lipophilic and hydrophilic statins contribute to the prevention of liver cancer. Moreover, the efficacy was influenced by the region and the specific type of statins used.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver NeoplasmsHumansIncidenceLovastatinSimvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsLovastatinSimvastatinhydrophilic statinsincidencelipophilic statinsLiver cancermeta-analysisstatin

Identifiers

PMID37393552
PMCPMC10661961
OpenAlexW4382894171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.